Biosimilars naming and prescribing policy in Australia
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 4
Abstract
To the Editor: I wanted to bring to your attention the following paper which was published in Volume 2/Year 2013/Issue 3 of the Generics and Biosimilars Initiative Journal. The Perspective paper titled Licensing and prescribing biosimilars in Australia [1], Professor David Power’s description of the Australian reimbursement system contains a number of factual errors. Left uncorrected those errors lead people to misunderstand the market for biosimilars in Australia.
Authors and Affiliations
Brendan Shaw
Keywords
Related Articles
- EP ID EP354662
- DOI 10.5639/gabij.2013.0204.048
- Views 104
- Downloads 0
Biosimilars naming, label transparency and authority of choice – survey findings among European physicians
Introduction: A survey of the views of European physicians on familiarity of biosimilar medicines has demonstrated the need for distinguishable non-proprietary names to be given to all biologicals. Methods: The Alliance...
Generics substitution in primary care: summary of the Dutch community pharmacies guidelines
Marketed medicines that have passed bioequivalence testing should in general be substitutable. However, for a variety of reasons, caution may be warranted, particularly with regard to narrow therapeutic index drugs and t...
Legislative efforts to limit prescription information sharing between patients and healthcare providers represent a serious threat to the health and safety of the American nation
Legislation in support of pharmacist notification to patients and providers of substitution of an interchangeable biologic for the originator biologic was recently vetoed in California. Automatic substitution of approved...
Clinical development, immunogenicity, and interchangeability of follow-on complex drugs
Although not derived from living sources, non-biological complex drug (NBCD) products have the immunogenicity and molecular complexity of biological drugs. NBCDs typically contain heterogenous mixtures of closely related...
A patient-centred paradigm for the biosimilars market
The advent of similar biological medicinal products or ‘biosimilars’ in Europe in the 2000s has led to development of a global biosimilars market and regulatory frameworks designed specifically for approval of biosimilar...